Acute coronary syndrome

News

BMS and J&J call time on oral anticoagulant milvexian in acute coronary syndrome, but are still running trials in atrial fibrillation and stroke.

News

Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.